{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T14:43:01Z","timestamp":1664980981812},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"DOI":"10.1007\/s00105-022-05049-7","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T11:03:07Z","timestamp":1662634987000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lebensqualit\u00e4t von Patienten mit Mycosis fungoides und S\u00e9zary-Syndrom"],"prefix":"10.1007","author":[{"given":"Manuel","family":"J\u00e4ger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"\u00d6zistanbullu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus-Detlev","family":"Klemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Tratzmiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"issue":"10","key":"5049_CR1","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1038\/bjc.2013.616","volume":"109","author":"T Illidge","year":"2013","unstructured":"Illidge\u00a0T, Chan\u00a0C, Counsell\u00a0N, Morris\u00a0S, Scarisbrick\u00a0J, Gilson\u00a0D et al (2013) Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T\u2011cell lymphoma. Br J Cancer 109(10):2566\u20132573. https:\/\/doi.org\/10.1038\/bjc.2013.616","journal-title":"Br J Cancer"},{"key":"5049_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger\u00a0F, Eder\u00a0J, Assaf\u00a0C, Bagot\u00a0M, Cozzio\u00a0A, Dummer\u00a0R, Gniadecki\u00a0R, Klemke\u00a0CD, Ortiz-Romero\u00a0PL, Papadavid\u00a0E, Pimpinelli\u00a0N, Quaglino\u00a0P, Ranki\u00a0A, Scarisbrick\u00a0J, Stadler\u00a0R, V\u00e4kev\u00e4\u00a0L, Vermeer\u00a0MH, Whittaker\u00a0S, Willemze\u00a0R, Knobler\u00a0R (2017) European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2017. Eur J Cancer 77:57\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.027","journal-title":"Eur J Cancer"},{"key":"5049_CR3","doi-asserted-by":"publisher","first-page":"CD008946","DOI":"10.1002\/14651858.CD008946.pub3","volume":"7","author":"A Valipour","year":"2020","unstructured":"Valipour\u00a0A, J\u00e4ger\u00a0M, Wu\u00a0P, Schmitt\u00a0J, Bunch\u00a0C, Weberschock\u00a0T (2020) Interventions for mycosis fungoides. Cochrane Database Syst Rev 7:CD8946. https:\/\/doi.org\/10.1002\/14651858.CD008946.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"5049_CR4","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/jdv.17570","volume":"35","author":"R Ottevanger","year":"2021","unstructured":"Ottevanger\u00a0R, van Beugen\u00a0S, Evers\u00a0AWM, Willemze\u00a0R, Vermeer\u00a0MH, Quint\u00a0KD (2021) Quality of life in patients with mycosis fungoides and S\u00e9zary syndrome: a\u00a0systematic review of the literature. J\u00a0Eur Acad Dermatol Venereol 35(12):2377\u20132387. https:\/\/doi.org\/10.1111\/jdv.17570","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5049_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjd.19252","volume":"184","author":"P Quaglino","year":"2021","unstructured":"Quaglino\u00a0P, Prince\u00a0HM, Cowan\u00a0R, Vermeer\u00a0M, Papadavid\u00a0E, Bagot\u00a0M et al (2021) Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 184(4):722\u2013730. https:\/\/doi.org\/10.1111\/bjd.19252","journal-title":"Br J Dermatol"},{"issue":"1","key":"5049_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/jid.2011.354","volume":"132","author":"T Nijsten","year":"2012","unstructured":"Nijsten\u00a0T (2012) Dermatology life quality index: time to move forward. J\u00a0Invest Dermatol 132(1):11\u201313. https:\/\/doi.org\/10.1038\/jid.2011.354","journal-title":"J Invest Dermatol"},{"issue":"5","key":"5049_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren\u00a0MM, Lasek\u00a0RJ, Quinn\u00a0LM, Mostow\u00a0EN, Zyzanski\u00a0SJ (1996) Skindex, a\u00a0quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J\u00a0Invest Dermatol 107(5):707\u2013713. https:\/\/doi.org\/10.1111\/1523-1747.ep12365600","journal-title":"J Invest Dermatol"},{"issue":"11","key":"5049_CR8","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","volume":"133","author":"MM Chren","year":"1997","unstructured":"Chren\u00a0MM, Lasek\u00a0RJ, Flocke\u00a0SA, Zyzanski\u00a0SJ (1997) Improved discriminative and evaluative capability of a\u00a0refined version of Skindex, a\u00a0quality-of-life instrument for patients with skin diseases. Arch Dermatol 133(11):1433\u20131440","journal-title":"Arch Dermatol"},{"issue":"2","key":"5049_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","volume":"30","author":"M-M Chren","year":"2012","unstructured":"Chren\u00a0M\u2011M (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30(2):231\u2013236. https:\/\/doi.org\/10.1016\/j.det.2011.11.003","journal-title":"Dermatol Clin"},{"issue":"3","key":"5049_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archderm.141.3.325","volume":"141","author":"M-F Demierre","year":"2005","unstructured":"Demierre\u00a0M\u2011F, Tien\u00a0A, Miller\u00a0D (2005) Health-related quality-of-life assessment in patients with cutaneous T\u2011cell lymphoma. Arch Dermatol 141(3):325\u2013330. https:\/\/doi.org\/10.1001\/archderm.141.3.325","journal-title":"Arch Dermatol"},{"issue":"1","key":"5049_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jpainsymman.2012.01.012","volume":"45","author":"A Wright","year":"2013","unstructured":"Wright\u00a0A, Wijeratne\u00a0A, Hung\u00a0T, Gao\u00a0W, Whittaker\u00a0S, Morris\u00a0S, Scarisbrick\u00a0J, Beynon\u00a0T (2013) Prevalence and severity of pruritus and quality of life in patients with cutaneous T\u2011cell lymphoma. J\u00a0Pain Symptom Manage 45(1):114\u2013119. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.01.012","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"5049_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2340\/00015555-2819","volume":"98","author":"S Porkert","year":"2017","unstructured":"Porkert\u00a0S, Lehner-Baumgartner\u00a0E, Valencak\u00a0J, Knobler\u00a0R, Riedl\u00a0E, Jonak\u00a0C (2017) Patients\u2019 illness perception as a tool to improve individual disease management in primary cutaneous lymphomas. Acta Dermatovenereol 98(2):240\u2013245. https:\/\/doi.org\/10.2340\/00015555-2819","journal-title":"Acta Dermatovenereol"},{"issue":"5","key":"5049_CR13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jdv.16021","volume":"34","author":"CM Herbosa","year":"2020","unstructured":"Herbosa\u00a0CM, Semenov\u00a0YR, Rosenberg\u00a0AR, Mehta-Shah\u00a0N, Musiek\u00a0AC (2020) Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and S\u00e9zary syndrome: comparison of generic and dermatology-specific instruments. J\u00a0Eur Acad Dermatol Venereol 34(5):995\u20131003. https:\/\/doi.org\/10.1111\/jdv.16021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"5049_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/bjd.18089","volume":"182","author":"K Molloy","year":"2020","unstructured":"Molloy\u00a0K, Jonak\u00a0C, Woei-A-Jin\u00a0FJSH, Guenova\u00a0E, Busschots\u00a0AM, Bervoets\u00a0A et al (2020) Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 182(3):770\u2013779. https:\/\/doi.org\/10.1111\/bjd.18089","journal-title":"Br J Dermatol"},{"issue":"18","key":"5049_CR15","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen\u00a0EA, Whittaker\u00a0S, Kim\u00a0YH, Duvic\u00a0M, Prince\u00a0HM, Lessin\u00a0SR, Wood\u00a0GS, Willemze\u00a0R, Demierre\u00a0M\u2011F, Pimpinelli\u00a0N, Bernengo\u00a0MG, Ortiz-Romero\u00a0PL, Bagot\u00a0M, Estrach\u00a0T, Guitart\u00a0J, Knobler\u00a0R, Sanches\u00a0JA, Iwatsuki\u00a0K, Sugaya\u00a0M, Dummer\u00a0R, Pittelkow\u00a0M, Hoppe\u00a0R, Parker\u00a0S, Geskin\u00a0L, Pinter-Brown\u00a0L, Girardi\u00a0M, Burg\u00a0G, Ranki\u00a0A, Vermeer\u00a0M, Horwitz\u00a0S, Heald\u00a0P, Rosen\u00a0S, Cerroni\u00a0L, Dreno\u00a0B, Vonderheid\u00a0EC (2011) Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a\u00a0consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J\u00a0Clin Oncol 29(18):2598\u20132607. https:\/\/doi.org\/10.1200\/JCO.2010.32.0630","journal-title":"J Clin Oncol"},{"issue":"10","key":"5049_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/jdv.15075","volume":"32","author":"DJ Lewis","year":"2018","unstructured":"Lewis\u00a0DJ, Huang\u00a0S, Duvic\u00a0M (2018) Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T\u2011cell lymphoma. J\u00a0Eur Acad Dermatol Venereol 32(10):1652\u20131656. https:\/\/doi.org\/10.1111\/jdv.15075","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"5049_CR17","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/cncr.22252","volume":"107","author":"M-F Demierre","year":"2006","unstructured":"Demierre\u00a0M\u2011F, Gan\u00a0S, Jones\u00a0J, Miller\u00a0DR (2006) Significant impact of cutaneous T\u2011cell lymphoma on patients\u2019 quality of life: results of a\u00a02005 National Cutaneous Lymphoma Foundation Survey. Cancer 107(10):2504\u20132511. https:\/\/doi.org\/10.1002\/cncr.22252","journal-title":"Cancer"},{"issue":"9","key":"5049_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1548-5315(11)70414-4","volume":"7","author":"M-F Demierre","year":"2010","unstructured":"Demierre\u00a0M\u2011F (2010) Mycosis fungoides and S\u00e9zary syndrome. The burden of pruritus. Community Oncol 7(9):399\u2013404. https:\/\/doi.org\/10.1016\/S1548-5315(11)70414-4","journal-title":"Community Oncol"},{"issue":"8","key":"5049_CR19","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1365-4632.2011.05188.x","volume":"51","author":"A Vij","year":"2012","unstructured":"Vij\u00a0A, Duvic\u00a0M (2012) Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 51(8):930\u2013934. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05188.x","journal-title":"Int J Dermatol"},{"issue":"2","key":"5049_CR20","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1097\/itx.0000000000000055","volume":"6","author":"G Farrah","year":"2021","unstructured":"Farrah\u00a0G, Spruijt\u00a0O, McCormack\u00a0C, Buelens\u00a0O, Lazarakis\u00a0S, Prince\u00a0M (2021) A systematic review on the management of pruritus in patients with cutaneous T\u2011cell lymphoma. Itch 6(2):e55\u2013e55. https:\/\/doi.org\/10.1097\/itx.0000000000000055","journal-title":"Itch"},{"issue":"5","key":"5049_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2340\/00015555-1265","volume":"92","author":"A Reich","year":"2012","unstructured":"Reich\u00a0A, Heisig\u00a0M, Phan\u00a0NQ, Taneda\u00a0K, Takamori\u00a0K, Takeuchi\u00a0S, Furue\u00a0M, Blome\u00a0C, Augustin\u00a0M, St\u00e4nder\u00a0S, Szepietowski\u00a0JC (2012) Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 92(5):497\u2013501. https:\/\/doi.org\/10.2340\/00015555-1265","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"5049_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1007\/s00105-004-0802-8","volume":"55","author":"A Brune","year":"2004","unstructured":"Brune\u00a0A, Metze\u00a0D, Luger\u00a0TA, St\u00e4nder\u00a0S (2004) Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon. Offene, nicht placebokontrollierte Anwendung bei 133\u00a0Patienten. Hautarzt 55(12):1130\u20131136. https:\/\/doi.org\/10.1007\/s00105-004-0802-8","journal-title":"Hautarzt"},{"issue":"14","key":"5049_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMc0906670","volume":"361","author":"A Duval","year":"2009","unstructured":"Duval\u00a0A, Dubertret\u00a0L (2009) Aprepitant as an antipruritic agent? N\u00a0Engl J Med 361(14):1415\u20131416. https:\/\/doi.org\/10.1056\/NEJMc0906670","journal-title":"N Engl J Med"},{"issue":"3","key":"5049_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2133.2010.10108.x","volume":"164","author":"N Booken","year":"2011","unstructured":"Booken\u00a0N, Heck\u00a0M, Nicolay\u00a0JP, Klemke\u00a0CD, Goerdt\u00a0S, Utikal\u00a0J (2011) Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T\u2011cell lymphoma. Br J Dermatol 164(3):665\u2013667. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10108.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"5049_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/s0885-3924(02)00645-0","volume":"25","author":"MP Davis","year":"2003","unstructured":"Davis\u00a0MP, Frandsen\u00a0JL, Walsh\u00a0D, Andresen\u00a0S, Taylor\u00a0S (2003) Mirtazapine for pruritus. J\u00a0Pain Symptom Manage 25(3):288\u2013291. https:\/\/doi.org\/10.1016\/s0885-3924(02)00645-0","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"5049_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaad.2006.04.025","volume":"55","author":"M-F Demierre","year":"2006","unstructured":"Demierre\u00a0M\u2011F, Taverna\u00a0J (2006) Mirtazapine and gabapentin for reducing pruritus in cutaneous T\u2011cell lymphoma. J\u00a0Am Acad Dermatol 55(3):543\u2013544. https:\/\/doi.org\/10.1016\/j.jaad.2006.04.025","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"5049_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ddg.14706_g","volume":"20","author":"E Dippel","year":"2022","unstructured":"Dippel\u00a0E, Chalid\u00a0A, Becker\u00a0JC, von Bergwelt-Baildon\u00a0M, Bernreiter\u00a0S, Cozzio\u00a0A et al (2022) S2k-Leitlinie \u2013 Kutane Lymphome (ICD10 C82\u2013C86): Update 2021. J\u00a0Dtsch Dermatol Ges 20(4):537\u2013555. https:\/\/doi.org\/10.1111\/ddg.14706_g","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05049-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-05049-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05049-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T14:25:34Z","timestamp":1664979934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-05049-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":27,"alternative-id":["5049"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-05049-7","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"20 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0J\u00e4ger, D.\u00a0\u00d6zistanbullu, C.\u2011D.\u00a0Klemke und S.\u00a0Tratzmiller und geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}